---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-085826"
form_type: "8-K"
ticker: "TBPH"
cik: "0001583107"
company_name: "Theravance Biopharma, Inc."
filed_at: "2024-08-05T23:59:59+00:00"
generated_at: "2026-05-31T13:07:23.890401+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Theravance Biopharma Q2 net loss $16.5M; YUPELRI net sales down 1%; CYPRESS enrollment delayed

## Summary
- Q2 2024 net loss of $16.5M vs $15.6M YoY; non-GAAP net loss from operations $6.3M.
- Viatris collaboration revenue $14.3M, up 4% YoY; implied 35% share of YUPELRI net sales $19.1M (down 1%).
- YUPELRI net sales (Viatris) $54.5M, down 1%; demand up 13% and hospital share hit all-time highs.
- CYPRESS study: last patient enrollment now expected mid-2025; top-line data ~6 months later.
- TRELEGY Q2 global net sales ~$1.1B (+40% YoY); up to $50M milestones achievable in 2024.

## SEC filing metadata
- accession: 0001104659-24-085826
- form_type: 8-K
- ticker: TBPH
- cik: 0001583107
- company_name: Theravance Biopharma, Inc.
- filed_at: 2024-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583107/000110465924085826/0001104659-24-085826-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583107/000110465924085826/tm2420794d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-085826
- JSON: https://secwatch.observer/filing/0001104659-24-085826.json
- Plain text: https://secwatch.observer/filing/0001104659-24-085826.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.